

Attorney Docket No.: KUZ0032US.NP  
Inventors: Hashimoto et al.  
Serial No.: 10/584,739  
Filing Date: June 26, 2006  
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the claims:**

Claim 1 (currently amended): A patch preparation comprising a support and an adhesive base, the adhesive base containing 8 to 50 mass % relative to total amount of the adhesive base of a rubber-system macromolecule having a double bond at least in a principal chain thereof and 0.1 to 10 mass % relative to entire amount of the preparation of a nonsteroidal anti-inflammatory analgesic drug and a combination of a hydrogenated rosin ester and a terpene resin as a tackifier for 10 to 20 mass % in total relative to total amount of the adhesive base, and the adhesive base further containing 0.5 to 20 mass % relative to entire amount of the preparation of a UVA blocker and/or a UVB blocker as a stabilizer for the rubber-system macromolecule.

Claim 2 (previously presented): The patch preparation according to claim 1, wherein the rubber-system macromolecule having a double bond at least in a principal chain thereof is selected from the group consisting of a styrene-isoprene-styrene block copolymer, a styrene-butadiene-styrene block copolymer, a styrene-butadiene copolymer, polyisoprene, and polybutadiene.

Claim 3 (previously presented): The patch preparation according to claim 1, wherein the nonsteroidal anti-inflammatory analgesic drug is selected from the group consisting of ketoprofen, tiaprofenic acid, suprofen,

Attorney Docket No.: KUZ0032US.NP  
Inventors: Hashimoto et al.  
Serial No.: 10/584,739  
Filing Date: June 26, 2006  
Page 3

tolmetin, carprofen, benoxaprofen, piroxicam, meloxicam, benzydamine, naproxen, felbinac, diclofenac, ibuprofen, diflunisal, azapropazone, etodolac, valdecoxib, celecoxib, rofecoxib, and pharmaceutically acceptable salts thereof.

Claim 4 (previously presented): The patch preparation according to claim 1, wherein the UVA blocker is selected from the group consisting of a dibenzoylmethane derivative and a benzotriazole derivative.

Claim 5 (previously presented): The patch preparation according to claim 4, wherein the UVA blocker is selected from the group consisting of 4-*tert*-butyl-4'-methoxydibenzoylmethane, 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy]disiloxanyl]propyl]phenol, and 2-(2-hydroxy-5-methoxyphenyl)-benzotriazole.

Claim 6 (previously presented): The patch preparation according to claim 1, wherein the UVB blocker is selected from the group consisting of a benzophenone derivative, a cinnamic acid derivative, a camphor derivative, an amino acid-based compound, and a benzoylpinacolone derivative.

Claim 7 (previously presented): The patch preparation according to claim 1, wherein it contains 2 to 10 mass % relative to entire amount of the preparation of the UVA blocker and/or the UVB blocker in the adhesive base.

Claims 8-10 (canceled)

Attorney Docket No.: KUZ0032US.NP  
Inventors: Hashimoto et al.  
Serial No.: 10/584,739  
Filing Date: June 26, 2006  
Page 4

Claim 11 (previously presented): The patch preparation according to claim 1, wherein it contains zinc oxide or titanium dioxide.